
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Long-term management and monitoring of established multiple sclerosis including DMT surveillance, symptom management optimization, and preventive care.">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/drafts/ms-chronic-management/">
      
      
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Multiple Sclerosis - Chronic Management - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#multiple-sclerosis-chronic-management" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Multiple Sclerosis - Chronic Management
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3" >
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_2" >
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/breakthrough-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_4" >
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barré Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/myasthenia-gravis-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_5" >
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/autoimmune-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_7" >
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/brain-metastases/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#section-a-action-items" class="md-nav__link">
    <span class="md-ellipsis">
      
        SECTION A: ACTION ITEMS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-b-reference-expand-as-needed" class="md-nav__link">
    <span class="md-ellipsis">
      
        SECTION B: REFERENCE (Expand as Needed)
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-a-dmt-monitoring-schedule-summary" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX A: DMT Monitoring Schedule Summary
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-b-pml-risk-stratification-natalizumab" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX B: PML Risk Stratification (Natalizumab)
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-c-dmt-washout-periods-for-pregnancy" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX C: DMT Washout Periods for Pregnancy
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  

  <nav class="md-tags" >
    
      
      
      
      
        <a href="../../tags/#tag:autoimmune" class="md-tag">autoimmune</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:chronic-management" class="md-tag">chronic-management</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:demyelinating" class="md-tag">demyelinating</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:multiple-sclerosis" class="md-tag">multiple-sclerosis</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:outpatient" class="md-tag">outpatient</a>
      
    
  </nav>


  
  


<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

<h1 id="multiple-sclerosis-chronic-management">Multiple Sclerosis - Chronic Management<a class="headerlink" href="#multiple-sclerosis-chronic-management" title="Permanent link">&para;</a></h1>
<p><strong>VERSION:</strong> 1.0
<strong>CREATED:</strong> January 27, 2026
<strong>STATUS:</strong> Draft - Pending Review</p>
<hr />
<p><strong>DIAGNOSIS:</strong> Multiple Sclerosis - Chronic Management</p>
<p><strong>ICD-10:</strong> G35 (Multiple sclerosis)</p>
<p><strong>SYNONYMS:</strong> MS maintenance, chronic MS, established MS, MS long-term care, relapsing-remitting MS maintenance, RRMS chronic, secondary progressive MS, SPMS, progressive MS management</p>
<p><strong>SCOPE:</strong> Long-term management of established MS including disease-modifying therapy (DMT) monitoring, symptom management optimization, surveillance imaging, preventive care, and special populations (pregnancy planning). Excludes acute MS relapse (see "MS - Exacerbation") and initial diagnostic workup (see "MS - New Diagnosis"). Primary focus is outpatient management with guidance for ED/hospital presentation of established MS patients.</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<hr />
<h2 id="section-a-action-items">SECTION A: ACTION ITEMS<a class="headerlink" href="#section-a-action-items" title="Permanent link">&para;</a></h2>
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs-routine-monitoring-all-ms-patients">1A. Essential/Core Labs - Routine Monitoring (All MS Patients)<a class="headerlink" href="#1a-essentialcore-labs-routine-monitoring-all-ms-patients" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC with differential</td>
<td>Baseline monitoring; DMT safety; infection assessment</td>
<td>Normal; ALC varies by DMT (see 1B)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>CMP</td>
<td>Metabolic panel; renal/hepatic function for DMT dosing</td>
<td>Normal</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>LFTs (AST, ALT, ALP, bilirubin)</td>
<td>DMT hepatotoxicity monitoring (interferons, teriflunomide, S1P modulators)</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Urinalysis with culture</td>
<td>UTI common MS comorbidity; can trigger pseudorelapse</td>
<td>Negative</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>TSH</td>
<td>Thyroid dysfunction (interferons, alemtuzumab)</td>
<td>Normal (0.4-4.0 mIU/L)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vitamin D, 25-hydroxy</td>
<td>Deficiency associated with disease activity</td>
<td>&gt;40 ng/mL (target &gt;50)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="1b-dmt-specific-monitoring-labs">1B. DMT-Specific Monitoring Labs<a class="headerlink" href="#1b-dmt-specific-monitoring-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTERFERONS (Avonex, Rebif, Betaseron, Plegridy)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Leukopenia, thrombocytopenia monitoring</td>
<td>WBC &gt;3000, ANC &gt;1500, Plt &gt;100K</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>TSH</td>
<td>Thyroid dysfunction</td>
<td>Normal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>GLATIRAMER ACETATE (Copaxone, Glatopa)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>No routine labs required</td>
<td>Minimal systemic toxicity</td>
<td>N/A</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>DIMETHYL/DIROXIMEL FUMARATE (Tecfidera, Vumerity)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Lymphopenia (PML risk if ALC &lt;500 for &gt;6 months)</td>
<td>ALC &gt;500/uL; discontinue if ALC &lt;500 x6mo</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>TERIFLUNOMIDE (Aubagio)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Leukopenia</td>
<td>WBC &gt;3000, ANC &gt;1500</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity (black box warning)</td>
<td>ALT &lt;3x ULN; discontinue if &gt;3x with symptoms</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Hypertension</td>
<td>&lt;140/90 mmHg</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>Teratogenic (Category X)</td>
<td>Negative</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>FINGOLIMOD (Gilenya)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Lymphopenia expected (therapeutic effect)</td>
<td>ALC 200-600/uL typical; concern if &lt;200</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>VZV IgG</td>
<td>Pre-treatment; vaccinate if negative</td>
<td>Positive (immune)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>SIPONIMOD (Mayzent)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Lymphopenia</td>
<td>ALC 200-600/uL typical</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>CYP2C9 genotype</td>
<td>Required before initiation; determines dosing</td>
<td><em>1/</em>3 or <em>2/</em>3: 1 mg dose; <em>3/</em>3: contraindicated</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>OZANIMOD (Zeposia) / PONESIMOD (Ponvory)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Lymphopenia</td>
<td>ALC 200-600/uL typical</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>NATALIZUMAB (Tysabri)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>JCV antibody with index</td>
<td>PML risk stratification</td>
<td>Negative preferred; if positive, index &lt;0.9 lower risk</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Infusion reactions; general monitoring</td>
<td>Normal</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>OCRELIZUMAB (Ocrevus) / OFATUMUMAB (Kesimpta) / UBLITUXIMAB (Briumvi)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Hepatitis B surface antigen, core antibody</td>
<td>Reactivation risk</td>
<td>Negative; if positive, HBV DNA and GI/ID consult</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Quantitative immunoglobulins (IgG, IgA, IgM)</td>
<td>Hypogammaglobulinemia risk</td>
<td>IgG &gt;400 mg/dL</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>CD19/CD20 B-cell count</td>
<td>Therapeutic monitoring</td>
<td>B-cell depletion expected</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>ALEMTUZUMAB (Lemtrada)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with platelet count</td>
<td>ITP, neutropenia (monthly x 48 months after last dose)</td>
<td>Platelets &gt;100K; report petechiae/bruising</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Serum creatinine, urinalysis</td>
<td>Anti-GBM nephropathy (monthly x 48 months)</td>
<td>Creatinine stable; UA negative for RBCs/protein</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>TSH</td>
<td>Autoimmune thyroid disease (quarterly x 48 months)</td>
<td>Normal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>CLADRIBINE (Mavenclad)</strong></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Lymphopenia (target); timing critical</td>
<td>ALC &gt;800 before year 2; monitoring at months 2 and 6</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Hepatotoxicity</td>
<td>AST/ALT &lt;3x ULN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="1c-rarespecialized-labs">1C. Rare/Specialized Labs<a class="headerlink" href="#1c-rarespecialized-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>JCV PCR (CSF)</td>
<td>Suspected PML (focal neuro symptoms on natalizumab/DMF/fingolimod)</td>
<td>Negative (if positive, confirms PML)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Serum natalizumab antibodies</td>
<td>Suspected infusion reactions or loss of efficacy</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Anti-drug antibodies (interferon)</td>
<td>Suspected neutralizing antibodies with breakthrough disease</td>
<td>Negative</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Serum neurofilament light chain (NfL)</td>
<td>Research/emerging; monitor subclinical disease activity</td>
<td>Low/stable (no established threshold)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pregnancy test (urine or serum)</td>
<td>Before DMT initiation or if pregnancy suspected</td>
<td>Negative before teratogenic DMTs</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line-surveillance-imaging">2A. Essential/First-line - Surveillance Imaging<a class="headerlink" href="#2a-essentialfirst-line-surveillance-imaging" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI brain with and without contrast (MS protocol)</td>
<td>Annual surveillance; 3-6 months after DMT change</td>
<td>No new/enlarging T2 lesions; no new enhancing lesions (NEDA-3)</td>
<td>GFR &lt;30; gadolinium allergy; pacemaker</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>MRI C-spine with and without contrast</td>
<td>Annual or with new symptoms; baseline if not done</td>
<td>No new cord lesions</td>
<td>GFR &lt;30; gadolinium allergy; pacemaker</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>MRI T-spine with and without contrast</td>
<td>Baseline; repeat if new lower extremity symptoms</td>
<td>No new cord lesions</td>
<td>GFR &lt;30; gadolinium allergy; pacemaker</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
</tbody>
</table>
<h3 id="2b-extended-dmt-specific-and-symptom-directed">2B. Extended - DMT-Specific and Symptom-Directed<a class="headerlink" href="#2b-extended-dmt-specific-and-symptom-directed" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI brain for PML surveillance (natalizumab, DMF, fingolimod)</td>
<td>q3-6 months if high JCV risk; q12 months if low risk</td>
<td>No new periventricular or subcortical lesions without enhancement</td>
<td>Standard MRI contraindications</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>OCT (optical coherence tomography)</td>
<td>Annual; baseline; after optic neuritis</td>
<td>Stable RNFL thickness (&gt;5 micron/year loss is pathological)</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Visual evoked potentials</td>
<td>Baseline; suspected subclinical optic nerve involvement</td>
<td>Stable P100 latency</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>ECG</td>
<td>S1P modulators (fingolimod, siponimod) first dose; baseline and annually</td>
<td>Normal sinus rhythm; PR &lt;200 ms; QTc &lt;500 ms</td>
<td>None</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Ophthalmology exam (macular OCT)</td>
<td>S1P modulators at 3-4 months; then annually</td>
<td>No macular edema</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pulmonary function tests</td>
<td>If respiratory symptoms; alemtuzumab monitoring</td>
<td>FVC &gt;80% predicted</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="2c-rarespecialized">2C. Rare/Specialized<a class="headerlink" href="#2c-rarespecialized" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET-CT</td>
<td>Suspected malignancy (lymphoma risk with immunosuppression)</td>
<td>No FDG-avid lesions</td>
<td>Pregnancy; uncontrolled diabetes</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Urodynamic studies</td>
<td>Refractory bladder symptoms</td>
<td>Defines neurogenic bladder type (hyperreflexic vs hyporeflexic)</td>
<td>Active UTI</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Video swallow study</td>
<td>Dysphagia or recurrent aspiration</td>
<td>Safe swallow; define texture modifications</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Sleep study (polysomnography)</td>
<td>Severe fatigue; suspected sleep apnea</td>
<td>AHI &lt;5/hour</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>DEXA scan</td>
<td>Long-term steroid exposure; mobility impairment; menopause</td>
<td>T-score &gt;-2.5</td>
<td>None</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="3-treatment">3. TREATMENT<a class="headerlink" href="#3-treatment" title="Permanent link">&para;</a></h2>
<h3 id="3a-acuteemergent-ms-patient-presenting-to-edhospital">3A. Acute/Emergent (MS Patient Presenting to ED/Hospital)<a class="headerlink" href="#3a-acuteemergent-ms-patient-presenting-to-edhospital" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continue home DMT</td>
<td>Various</td>
<td>Established MS patient on DMT</td>
<td>Home dose :: Home route :: per home schedule :: Verify home DMT and continue unless contraindicated; consult neurology for infusion therapies</td>
<td>Varies by DMT</td>
<td>Per DMT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Methylprednisolone IV</td>
<td>IV</td>
<td>Acute MS relapse</td>
<td>1000 mg :: IV :: daily x 3-5 days :: 1000 mg IV daily for 3-5 days; infuse over 1 hour</td>
<td>Active infection; uncontrolled diabetes; psychosis</td>
<td>Glucose q6h; BP; mood</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>PO</td>
<td>GI prophylaxis during steroids</td>
<td>20 mg daily; 40 mg daily :: PO :: daily :: 20-40 mg PO daily during steroids</td>
<td>PPI allergy</td>
<td>None</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Insulin sliding scale</td>
<td>SC</td>
<td>Steroid-induced hyperglycemia</td>
<td>Per protocol :: SC :: PRN :: Per protocol if glucose &gt;180 mg/dL</td>
<td>Hypoglycemia risk</td>
<td>Glucose q6h</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-fatigue">3B. Symptomatic Treatments - Fatigue<a class="headerlink" href="#3b-symptomatic-treatments-fatigue" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amantadine</td>
<td>PO</td>
<td>MS-related fatigue (first-line)</td>
<td>100 mg qAM; 100 mg BID :: PO :: :: Start 100 mg every morning; may add 100 mg early afternoon (before 2 PM to avoid insomnia); max 200 mg/day</td>
<td>Renal impairment (adjust dose CrCl &lt;50); seizure history; uncontrolled glaucoma</td>
<td>Livedo reticularis; ankle edema; hallucinations; insomnia</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Modafinil</td>
<td>PO</td>
<td>MS-related fatigue (second-line); Schedule IV</td>
<td>100 mg qAM; 200 mg qAM :: PO :: :: Start 100 mg every morning; may increase to 200 mg; max 200 mg daily; take early AM</td>
<td>Cardiac arrhythmia; left ventricular hypertrophy; mitral valve prolapse</td>
<td>BP; HR; may reduce hormonal contraception efficacy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Armodafinil</td>
<td>PO</td>
<td>MS-related fatigue; longer half-life; Schedule IV</td>
<td>150 mg qAM :: PO :: :: 150 mg every morning; longer duration than modafinil</td>
<td>Same as modafinil</td>
<td>Same as modafinil</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>PO</td>
<td>Refractory fatigue; Schedule II</td>
<td>5 mg BID; 10 mg BID; 20 mg BID :: PO :: :: Start 5 mg morning and noon; titrate by 5-10 mg/week; max 60 mg/day; avoid afternoon dosing</td>
<td>Marked anxiety; glaucoma; motor tics; MAOIs; severe hypertension</td>
<td>BP; HR; appetite; mood; growth (rare in adults)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-spasticity">3B. Symptomatic Treatments - Spasticity<a class="headerlink" href="#3b-symptomatic-treatments-spasticity" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baclofen</td>
<td>PO</td>
<td>Spasticity (first-line)</td>
<td>5 mg TID; 10 mg TID; 20 mg TID; 25 mg TID :: PO :: :: Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day divided TID-QID</td>
<td>Renal impairment (reduce dose); avoid abrupt withdrawal</td>
<td>Sedation; weakness; AVOID ABRUPT DISCONTINUATION (withdrawal seizures, hallucinations)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Tizanidine</td>
<td>PO</td>
<td>Spasticity (alternative to baclofen; less weakness)</td>
<td>2 mg qHS; 4 mg TID; 8 mg TID :: PO :: :: Start 2 mg qHS or TID; increase by 2-4 mg every 3-4 days; max 36 mg/day divided TID</td>
<td>Hepatic impairment; concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors)</td>
<td>LFTs at baseline, 1, 3, 6 months; hypotension; sedation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td>PO</td>
<td>Spasticity with muscle spasm component</td>
<td>5 mg TID; 10 mg TID :: PO :: :: 5-10 mg TID; max 30 mg/day; short-term use preferred</td>
<td>Cardiac arrhythmia; heart block; CHF; MAOIs; hyperthyroidism</td>
<td>Anticholinergic effects; sedation; cardiac</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Dantrolene</td>
<td>PO</td>
<td>Spasticity refractory to baclofen/tizanidine</td>
<td>25 mg daily; 25 mg TID; 50 mg TID; 100 mg TID :: PO :: :: Start 25 mg daily; increase by 25 mg every 4-7 days; max 100 mg QID</td>
<td>Active liver disease; concurrent hepatotoxic drugs</td>
<td>LFTs monthly x 6 months, then periodically; hepatotoxicity (black box)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>OnabotulinumtoxinA</td>
<td>IM</td>
<td>Focal spasticity (upper or lower extremity)</td>
<td>100-400 units total :: IM :: q12 weeks :: Dose varies by muscle group; 100-400 units total; repeat every 12 weeks</td>
<td>Infection at injection site; myasthenia gravis; ALS</td>
<td>Systemic weakness (rare); local weakness</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Intrathecal baclofen pump</td>
<td>IT</td>
<td>Severe refractory spasticity affecting quality of life</td>
<td>Continuous infusion :: IT :: :: Trial 50-100 mcg bolus; maintenance typically 100-400 mcg/day; pump refill q1-3 months</td>
<td>Active infection; pump site not suitable</td>
<td>Pump alarm; reservoir level; overdose symptoms (sedation); withdrawal symptoms</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-neuropathic-pain">3B. Symptomatic Treatments - Neuropathic Pain<a class="headerlink" href="#3b-symptomatic-treatments-neuropathic-pain" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabapentin</td>
<td>PO</td>
<td>Neuropathic pain (first-line); dysesthesias; Lhermitte sign</td>
<td>300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day</td>
<td>Renal impairment (adjust dose per CrCl)</td>
<td>Sedation; dizziness; peripheral edema; ataxia</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>PO</td>
<td>Neuropathic pain (first-line alternative); Schedule V</td>
<td>75 mg BID; 150 mg BID; 225 mg BID; 300 mg BID :: PO :: :: Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID</td>
<td>Renal impairment (adjust per CrCl)</td>
<td>Sedation; weight gain; peripheral edema</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>PO</td>
<td>Neuropathic pain with comorbid depression</td>
<td>30 mg daily; 60 mg daily; 90 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day</td>
<td>Hepatic impairment; MAOIs; uncontrolled narrow-angle glaucoma</td>
<td>Nausea (transient); BP; discontinuation syndrome (taper)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>PO</td>
<td>Neuropathic pain; nocturnal pain; insomnia</td>
<td>10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS</td>
<td>Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma</td>
<td>Anticholinergic effects; ECG if dose &gt;100 mg/day; weight gain</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>PO</td>
<td>Neuropathic pain; less sedating than amitriptyline</td>
<td>10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS</td>
<td>Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma</td>
<td>Anticholinergic effects; ECG if dose &gt;100 mg/day</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>PO</td>
<td>Trigeminal neuralgia in MS</td>
<td>100 mg BID; 200 mg BID; 400 mg BID :: PO :: :: Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day</td>
<td>AV block; bone marrow suppression; MAOIs</td>
<td>CBC; LFTs; sodium; HLA-B*1502 in Asian ancestry (SJS risk)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>PO</td>
<td>Trigeminal neuralgia (better tolerated than carbamazepine)</td>
<td>300 mg BID; 600 mg BID; 900 mg BID :: PO :: :: Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID</td>
<td>Hypersensitivity to carbamazepine</td>
<td>Sodium (hyponatremia more common); HLA-B*1502 screening</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-bladder-dysfunction">3B. Symptomatic Treatments - Bladder Dysfunction<a class="headerlink" href="#3b-symptomatic-treatments-bladder-dysfunction" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxybutynin IR</td>
<td>PO</td>
<td>Detrusor hyperreflexia; urinary urgency/frequency</td>
<td>5 mg BID; 5 mg TID :: PO :: :: Start 5 mg BID-TID; max 5 mg QID</td>
<td>Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction</td>
<td>Dry mouth; constipation; COGNITIVE IMPAIRMENT (avoid in elderly)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Oxybutynin ER</td>
<td>PO</td>
<td>Urinary urgency (fewer CNS effects than IR)</td>
<td>5 mg daily; 10 mg daily; 15 mg daily :: PO :: :: Start 5-10 mg daily; max 30 mg daily</td>
<td>Same as IR</td>
<td>Same but less cognitive impairment</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Solifenacin</td>
<td>PO</td>
<td>Urinary urgency (better CNS profile)</td>
<td>5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily</td>
<td>Urinary retention; gastric retention; uncontrolled narrow-angle glaucoma</td>
<td>Dry mouth; constipation; preferred if cognitive concerns</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Mirabegron</td>
<td>PO</td>
<td>Urinary urgency (beta-3 agonist; no anticholinergic effects)</td>
<td>25 mg daily; 50 mg daily :: PO :: :: Start 25 mg daily; may increase to 50 mg daily</td>
<td>Uncontrolled hypertension; severe hepatic impairment</td>
<td>BP monitoring; well-tolerated; fewer cognitive effects</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vibegron</td>
<td>PO</td>
<td>Urinary urgency (newer beta-3 agonist)</td>
<td>75 mg daily :: PO :: :: 75 mg once daily; no titration needed</td>
<td>Severe hepatic impairment</td>
<td>BP; well-tolerated</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Tamsulosin</td>
<td>PO</td>
<td>Urinary retention; hesitancy (detrusor-sphincter dyssynergia)</td>
<td>0.4 mg daily :: PO :: :: 0.4 mg daily 30 minutes after same meal each day</td>
<td>Severe sulfonamide allergy (caution)</td>
<td>Orthostatic hypotension; retrograde ejaculation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Intermittent self-catheterization</td>
<td>—</td>
<td>Urinary retention (PVR &gt;100-200 mL)</td>
<td>Per protocol :: — :: 4-6x daily :: Clean technique; frequency based on PVR and symptoms</td>
<td>Unable to perform; urethral stricture</td>
<td>UTI frequency; bladder diary; PVR</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>OnabotulinumtoxinA (bladder)</td>
<td>Cystoscopic</td>
<td>Refractory detrusor hyperreflexia</td>
<td>100-200 units :: Cystoscopic :: q6-12 months :: 100 units (start); may increase to 200 units; cystoscopic injection</td>
<td>UTI; urinary retention not willing to catheterize</td>
<td>PVR (may require ISC); UTI</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-depression-and-anxiety">3B. Symptomatic Treatments - Depression and Anxiety<a class="headerlink" href="#3b-symptomatic-treatments-depression-and-anxiety" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sertraline</td>
<td>PO</td>
<td>Depression in MS (first-line)</td>
<td>50 mg daily; 100 mg daily; 150 mg daily; 200 mg daily :: PO :: :: Start 50 mg daily; increase by 25-50 mg every 1-2 weeks; max 200 mg daily</td>
<td>Concurrent MAOIs; pimozide</td>
<td>Suicidality monitoring weeks 1-4; serotonin syndrome</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>PO</td>
<td>Depression; anxiety in MS</td>
<td>10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; may increase to 20 mg after 1 week; max 20 mg daily</td>
<td>Concurrent MAOIs; QT prolongation</td>
<td>QTc if risk factors or dose &gt;10 mg; suicidality monitoring</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Bupropion SR/XL</td>
<td>PO</td>
<td>Depression; fatigue; no sexual side effects</td>
<td>150 mg daily; 150 mg BID; 300 mg XL daily :: PO :: :: Start 150 mg SR daily; increase to 150 mg SR BID or 300 mg XL daily; max 400 mg/day</td>
<td>Seizure disorder; eating disorders; abrupt alcohol/benzo withdrawal</td>
<td>Seizure risk; insomnia; agitation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Venlafaxine XR</td>
<td>PO</td>
<td>Depression with pain component; anxiety</td>
<td>75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5-75 mg daily; increase by 75 mg every 4-7 days; max 225 mg daily</td>
<td>Uncontrolled hypertension; MAOIs</td>
<td>BP monitoring; discontinuation syndrome (taper slowly)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>PO</td>
<td>Depression with neuropathic pain</td>
<td>30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day</td>
<td>Hepatic impairment; MAOIs; narrow-angle glaucoma</td>
<td>Nausea; BP; discontinuation syndrome</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-gaitmobility">3B. Symptomatic Treatments - Gait/Mobility<a class="headerlink" href="#3b-symptomatic-treatments-gaitmobility" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalfampridine</td>
<td>PO</td>
<td>Walking impairment in MS (improves walking speed)</td>
<td>10 mg q12h :: PO :: :: 10 mg every 12 hours (MUST be exactly 12 hours apart); do NOT exceed 20 mg/day; swallow whole</td>
<td>Seizure history; CrCl &lt;50 mL/min; history of seizure on dalfampridine</td>
<td>Seizure risk (dose-dependent); UTI; dizziness; insomnia</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-cognitive-impairment">3B. Symptomatic Treatments - Cognitive Impairment<a class="headerlink" href="#3b-symptomatic-treatments-cognitive-impairment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive rehabilitation therapy</td>
<td>—</td>
<td>MS-related cognitive impairment</td>
<td>Per protocol :: — :: 1-2x weekly :: Referral to neuropsychology or speech therapy for structured cognitive exercises</td>
<td>None</td>
<td>Compliance; functional outcomes</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Donepezil</td>
<td>PO</td>
<td>Cognitive impairment (off-label; limited evidence)</td>
<td>5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS; may increase to 10 mg after 4-6 weeks</td>
<td>GI bleeding; cardiac conduction disease</td>
<td>Nausea; diarrhea; bradycardia; vivid dreams</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3b-symptomatic-treatments-other">3B. Symptomatic Treatments - Other<a class="headerlink" href="#3b-symptomatic-treatments-other" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextromethorphan-quinidine (Nuedexta)</td>
<td>PO</td>
<td>Pseudobulbar affect (PBA)</td>
<td>20/10 mg daily; 20/10 mg q12h :: PO :: :: Start 20/10 mg daily x 7 days; then 20/10 mg every 12 hours</td>
<td>QT prolongation; MAOIs; concurrent quinidine/quinine</td>
<td>ECG at baseline; QTc monitoring; drug interactions (CYP2D6)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Propranolol</td>
<td>PO</td>
<td>Action tremor in MS</td>
<td>20 mg BID; 40 mg BID; 80 mg BID :: PO :: :: Start 20 mg BID; increase by 20-40 mg every 3-7 days; max 320 mg/day</td>
<td>Asthma/COPD; bradycardia; heart block; decompensated CHF</td>
<td>HR; BP; fatigue; depression</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Primidone</td>
<td>PO</td>
<td>Tremor refractory to propranolol</td>
<td>25 mg qHS; 50 mg TID; 125 mg TID :: PO :: :: Start 25 mg qHS; increase by 25 mg weekly; usual 50-250 mg TID</td>
<td>Porphyria; phenobarbital hypersensitivity</td>
<td>Severe sedation initially; ataxia; cognitive effects</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Polyethylene glycol 3350</td>
<td>PO</td>
<td>Constipation (common with immobility, anticholinergics)</td>
<td>17 g daily; 17 g BID :: PO :: :: 17 g (1 capful) in 8 oz liquid daily; adjust to effect; may take 1-3 days</td>
<td>Bowel obstruction; ileus</td>
<td>Electrolytes if prolonged use</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="3c-second-linerefractory-acute-treatments">3C. Second-line/Refractory Acute Treatments<a class="headerlink" href="#3c-second-linerefractory-acute-treatments" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasmapheresis (PLEX)</td>
<td>—</td>
<td>Steroid-refractory acute relapse</td>
<td>5-7 exchanges :: — :: over 10-14 days :: 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange</td>
<td>Hemodynamic instability; sepsis; central line contraindication</td>
<td>BP; electrolytes; coagulation; fibrinogen; line infection</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>IVIG</td>
<td>IV</td>
<td>Steroid-refractory relapse (alternative to PLEX)</td>
<td>0.4 g/kg/day :: IV :: x 5 days :: 0.4 g/kg/day x 5 days (total 2 g/kg)</td>
<td>IgA deficiency; renal failure; thrombosis history</td>
<td>Renal function; headache; aseptic meningitis; thrombosis</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
</tr>
</tbody>
</table>
<h3 id="3d-disease-modifying-therapies-monitoring-protocols">3D. Disease-Modifying Therapies - Monitoring Protocols<a class="headerlink" href="#3d-disease-modifying-therapies-monitoring-protocols" title="Permanent link">&para;</a></h3>
<p><em>DMT monitoring is critical for chronic MS management. See Section 1B for specific lab requirements. Below are monitoring schedules by DMT class.</em></p>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Pre-Treatment Requirements</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INJECTABLE DMTs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Interferon beta (any formulation)</td>
<td>IM/SC</td>
<td>RRMS; established patient on therapy</td>
<td>Per product labeling :: IM/SC :: :: Continue established regimen</td>
<td>CBC, LFTs, TSH at baseline</td>
<td>Decompensated liver disease; depression (relative)</td>
<td>CBC, LFTs q3-6 months; TSH annually; depression screening</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Glatiramer acetate (any formulation)</td>
<td>SC</td>
<td>RRMS; established patient</td>
<td>20 mg daily or 40 mg TIW :: SC :: :: Continue established regimen</td>
<td>None required</td>
<td>Hypersensitivity</td>
<td>Injection site reactions; post-injection reaction (self-limited)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>ORAL DMTs - MODERATE EFFICACY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Dimethyl fumarate (Tecfidera)</td>
<td>PO</td>
<td>RRMS; established patient</td>
<td>240 mg BID :: PO :: :: Continue 240 mg BID with food</td>
<td>CBC, LFTs</td>
<td>ALC &lt;500 for &gt;6 months (discontinue); PML risk</td>
<td>CBC q6 months; LFTs periodically; MRI surveillance for PML</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Diroximel fumarate (Vumerity)</td>
<td>PO</td>
<td>RRMS; less GI side effects than Tecfidera</td>
<td>462 mg BID :: PO :: :: Continue 462 mg BID with food</td>
<td>CBC, LFTs</td>
<td>ALC &lt;500 for &gt;6 months (discontinue); PML risk</td>
<td>CBC q6 months; LFTs periodically; MRI surveillance for PML</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Teriflunomide (Aubagio)</td>
<td>PO</td>
<td>RRMS; established patient</td>
<td>7 mg or 14 mg daily :: PO :: :: Continue established dose</td>
<td>LFTs monthly x 6 months; TB test; BP; pregnancy test</td>
<td>Pregnancy (Category X); severe hepatic impairment</td>
<td>LFTs monthly x 6 months, then periodically; BP; pregnancy test PRN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>ORAL DMTs - S1P MODULATORS (HIGH EFFICACY)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Fingolimod (Gilenya)</td>
<td>PO</td>
<td>RRMS; established patient</td>
<td>0.5 mg daily :: PO :: :: Continue 0.5 mg daily</td>
<td>First-dose observation completed; VZV immune; macular OCT; ECG</td>
<td>Cardiac conduction issues; recent MI/stroke; macular edema</td>
<td>Macular OCT annually; CBC q6-12 months; LFTs annually; MRI for PML surveillance</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Siponimod (Mayzent)</td>
<td>PO</td>
<td>SPMS or RRMS; established patient</td>
<td>1 mg or 2 mg daily (per CYP2C9) :: PO :: :: Continue established dose per genotype</td>
<td>CYP2C9 genotype; first-dose observation; macular OCT</td>
<td>CYP2C9 <em>3/</em>3; cardiac conduction issues; macular edema</td>
<td>Macular OCT annually; CBC q6-12 months; LFTs annually</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Ozanimod (Zeposia)</td>
<td>PO</td>
<td>RRMS; established patient</td>
<td>0.92 mg daily :: PO :: :: Continue 0.92 mg daily</td>
<td>Macular OCT; ECG (no first-dose observation required)</td>
<td>Cardiac conduction issues; recent MI/stroke; MAOIs</td>
<td>Macular OCT at 3-4 months then annually; CBC; LFTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Ponesimod (Ponvory)</td>
<td>PO</td>
<td>RRMS; established patient</td>
<td>20 mg daily :: PO :: :: Continue 20 mg daily</td>
<td>Macular OCT; ECG (no first-dose observation required)</td>
<td>Cardiac conduction issues; recent MI/stroke</td>
<td>Macular OCT at 3-4 months then annually; CBC; LFTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>ORAL DMTs - HIGH EFFICACY OTHER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Cladribine (Mavenclad)</td>
<td>PO</td>
<td>RRMS/SPMS; induction therapy</td>
<td>1.75 mg/kg/year x 2 years :: PO :: :: Year 1 and Year 2 only; no treatment years 3-4</td>
<td>ALC &gt;800 before each year; LFTs; HIV; Hep B/C</td>
<td>Active infection; HIV; malignancy; pregnancy</td>
<td>CBC at months 2 and 6 each treatment year; malignancy screening</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>INFUSION DMTs - HIGH EFFICACY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Natalizumab (Tysabri)</td>
<td>IV</td>
<td>RRMS; established patient</td>
<td>300 mg q4 weeks or extended q6 weeks :: IV :: :: Standard interval q4 weeks; extended interval dosing (EID) q6 weeks if stable and JCV negative</td>
<td>JCV antibody q6 months; REMS enrollment</td>
<td>JCV+ with index &gt;1.5 and prior immunosuppression (high PML risk)</td>
<td>JCV q6 months; MRI q3-6 months (high risk) or q6-12 months (low risk) for PML surveillance</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Ocrelizumab (Ocrevus)</td>
<td>IV</td>
<td>RRMS/PPMS; established patient</td>
<td>600 mg q6 months :: IV :: :: 600 mg IV every 6 months; premedicate</td>
<td>Hepatitis B screening; TB test; immunoglobulins</td>
<td>Active Hepatitis B; active infection</td>
<td>IgG annually; infection monitoring; infusion reactions</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Ofatumumab (Kesimpta)</td>
<td>SC</td>
<td>RRMS; established patient</td>
<td>20 mg monthly :: SC :: :: 20 mg SC monthly; self-administered at home</td>
<td>Hepatitis B screening; TB test; immunoglobulins</td>
<td>Active Hepatitis B; active infection</td>
<td>IgG annually; infection monitoring</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Ublituximab (Briumvi)</td>
<td>IV</td>
<td>RRMS; established patient</td>
<td>450 mg q6 months :: IV :: :: 450 mg IV every 24 weeks (after initial doses); 1-hour infusion</td>
<td>Hepatitis B screening; TB test; immunoglobulins</td>
<td>Active Hepatitis B; active infection</td>
<td>IgG annually; infection monitoring; infusion reactions</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Alemtuzumab (Lemtrada)</td>
<td>IV</td>
<td>RRMS; established patient post-induction</td>
<td>No further dosing unless rebound :: IV :: :: Monitoring continues 48 months after last infusion even without additional dosing</td>
<td>REMS enrollment; extensive baseline labs</td>
<td>Active infection; ongoing autoimmune disease</td>
<td>CBC monthly x 48 months; TSH q3 months x 48 months; creatinine/UA monthly x 48 months</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-referrals-consults">4A. Referrals &amp; Consults<a class="headerlink" href="#4a-referrals-consults" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS specialist/Neuroimmunology for annual comprehensive review and DMT optimization</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Neuro-ophthalmology for visual complaints, OCT monitoring, or suspected optic neuritis</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Physical therapy for gait training, balance exercises, and fall prevention given progressive mobility decline</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Occupational therapy for ADL assessment, energy conservation strategies, and adaptive equipment</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Speech therapy for dysphagia evaluation given brainstem involvement or swallowing concerns</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Neuropsychology for formal cognitive testing if subjective or objective cognitive decline</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Cognitive rehabilitation (speech therapy or neuropsychology) for documented cognitive impairment</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Urology for refractory bladder symptoms, recurrent UTIs, or urodynamic testing consideration</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Psychiatry for depression, anxiety, or adjustment disorders not responding to first-line treatment</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Pain management for refractory neuropathic pain not responding to multiple first-line agents</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Physiatry/Rehabilitation medicine for comprehensive rehabilitation planning and spasticity management</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Social work for disability planning, insurance navigation, and community resource connection</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Genetic counseling if considering pregnancy with strong family history or known genetic mutations</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>High-risk OB for pregnancy planning discussion in women on DMTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Infusion center for DMT administration and monitoring</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Palliative care for advanced MS with significant symptom burden or goals of care discussions</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
</tbody>
</table>
<h3 id="4b-patient-instructions">4B. Patient Instructions<a class="headerlink" href="#4b-patient-instructions" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return immediately if rapid vision loss, new weakness, numbness, or difficulty walking develops (may indicate relapse requiring steroids)</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Report fever or signs of infection promptly as immunomodulatory DMTs increase infection risk</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Continue DMT as prescribed unless instructed otherwise by neurology - do not stop without discussing</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Avoid live vaccines while on immunosuppressive DMTs (fingolimod, siponimod, cladribine, anti-CD20 therapies, alemtuzumab)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Heat may temporarily worsen symptoms (Uhthoff phenomenon) - use cooling strategies; this is NOT a new relapse</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Maintain symptom diary noting new symptoms, fatigue levels, and bladder/bowel patterns</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Do not stop baclofen or tizanidine abruptly - taper under medical supervision to avoid withdrawal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Report any skin changes, new moles, or suspicious lesions given increased malignancy risk with some DMTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Women of childbearing potential: discuss pregnancy plans with MS specialist before conception given DMT-specific washout requirements</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Report unusual fatigue, shortness of breath, chest pain, or palpitations if on S1P modulators (cardiac effects)</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>If on natalizumab: report any new neurological symptoms, especially if subtle (confusion, personality change, clumsiness) as may indicate PML</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Take dalfampridine exactly 12 hours apart and never exceed 2 doses per day (seizure risk)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<h3 id="4c-lifestyle-prevention">4C. Lifestyle &amp; Prevention<a class="headerlink" href="#4c-lifestyle-prevention" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation - smoking accelerates MS progression, increases relapse rate, and worsens disability</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Vitamin D supplementation 2000-5000 IU daily to maintain serum 25-OH vitamin D &gt;40 ng/mL (target &gt;50 ng/mL)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Regular aerobic exercise 150 minutes per week as tolerated - improves fatigue, mood, mobility, and may slow progression</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Aquatic therapy/swimming - allows exercise with built-in cooling and reduced fall risk</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Resistance training 2-3 times weekly for strength maintenance and bone health</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Stress management techniques as stress may trigger pseudorelapses and worsen fatigue</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Sleep hygiene - ensure 7-8 hours nightly; address sleep disorders contributing to fatigue</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Avoid excessive heat exposure (hot tubs, saunas, exercising in heat) - use cooling vests for outdoor activities</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Fall prevention: remove loose rugs, ensure adequate lighting, use assistive devices (cane, walker) as needed</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Complete recommended vaccinations before starting immunosuppressive DMTs - inactivated vaccines safe on most DMTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Annual influenza vaccine (inactivated) and COVID-19 vaccines per current guidelines (timing around infusions for anti-CD20)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Limit alcohol intake as it can worsen balance, cognitive symptoms, and interact with medications</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Mediterranean diet pattern may have anti-inflammatory benefits based on observational data</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>DEXA scan for bone density monitoring if prolonged steroid exposure, immobility, or menopause</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<h3 id="4d-vaccination-guidance">4D. Vaccination Guidance<a class="headerlink" href="#4d-vaccination-guidance" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIVE vaccines (MMR, varicella, zoster live, yellow fever) contraindicated on fingolimod, siponimod, ozanimod, ponesimod, cladribine, anti-CD20 therapies, alemtuzumab</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Recombinant zoster vaccine (Shingrix) - 2 doses recommended for patients &gt;50 years; safe on most DMTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Ensure VZV immunity (IgG) before starting S1P modulators - vaccinate and wait 4 weeks if non-immune</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Hepatitis B vaccination if non-immune before starting anti-CD20 therapies (ocrelizumab, ofatumumab, ublituximab)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Pneumococcal vaccination (PCV20 or PCV15 + PPSV23) recommended especially before immunosuppressive DMTs</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>COVID-19 vaccination: complete primary series and boosters; for anti-CD20 therapies, time 2-4 weeks before next infusion or 12+ weeks after last infusion</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>HPV vaccination for eligible patients &lt;45 years, especially before cladribine or alemtuzumab (malignancy screening required)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Influenza vaccine annually (inactivated) - safe on all DMTs; for anti-CD20, optimize timing but do not delay if timing not ideal</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<h3 id="4e-pregnancy-planning">4E. Pregnancy Planning<a class="headerlink" href="#4e-pregnancy-planning" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discuss pregnancy plans with MS specialist before conception - most DMTs require washout period</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Teriflunomide: Category X - requires accelerated elimination procedure (cholestyramine or activated charcoal) before conception; verify undetectable levels</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Fingolimod: discontinue 2 months before conception; rebound risk after stopping</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Siponimod, ozanimod, ponesimod: discontinue 7-10 days before conception (shorter half-lives than fingolimod)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Natalizumab: can continue until pregnancy confirmed; some continue through pregnancy in high-activity disease with shared decision-making</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Anti-CD20 therapies: discontinue 6-12 months before conception; B-cell recovery variable</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Cladribine: recommend effective contraception for 6 months after last dose (men and women)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Alemtuzumab: recommend contraception for 4 months after last infusion</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Glatiramer acetate and interferon-beta: no evidence of harm; may continue during pregnancy if needed (glatiramer preferred)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>High-risk OB referral for all MS pregnancies given increased complication risk and postpartum relapse risk</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Plan for early postpartum DMT restart (relapses increase 3-6 months postpartum)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<hr />
<hr />
<h2 id="section-b-reference-expand-as-needed">SECTION B: REFERENCE (Expand as Needed)<a class="headerlink" href="#section-b-reference-expand-as-needed" title="Permanent link">&para;</a></h2>
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<p><em>For established MS patients presenting with new symptoms, consider:</em></p>
<table>
<thead>
<tr>
<th>Alternative Diagnosis</th>
<th>Key Distinguishing Features</th>
<th>Tests to Differentiate</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS relapse vs pseudorelapse</td>
<td>True relapse: new neuroinflammation; Pseudorelapse: symptom worsening from infection, heat, stress without new inflammation</td>
<td>MRI with contrast (new enhancing lesions = true relapse); infection workup (UTI, URI)</td>
</tr>
<tr>
<td>Progressive multifocal leukoencephalopathy (PML)</td>
<td>Subacute cognitive/behavioral change, visual, motor symptoms; on natalizumab, DMF, fingolimod</td>
<td>MRI (subcortical non-enhancing lesions); CSF JCV PCR</td>
</tr>
<tr>
<td>CNS infection</td>
<td>Fever, meningeal signs, rapid deterioration; immunosuppressed</td>
<td>Lumbar puncture; blood cultures; imaging</td>
</tr>
<tr>
<td>Comorbid stroke/TIA</td>
<td>Sudden onset; vascular risk factors; non-MS territory</td>
<td>MRI DWI; vascular imaging</td>
</tr>
<tr>
<td>Medication side effect</td>
<td>Temporal relationship to new medication or dose change</td>
<td>Medication review; trial discontinuation</td>
</tr>
<tr>
<td>Functional neurological disorder</td>
<td>Inconsistent exam; non-anatomical patterns; psychiatric comorbidity</td>
<td>Clinical assessment; normal MRI</td>
</tr>
<tr>
<td>B12 deficiency myelopathy</td>
<td>Progressive; dorsal column signs; may coexist with MS</td>
<td>B12, MMA, homocysteine</td>
</tr>
<tr>
<td>Secondary malignancy</td>
<td>Progressive; atypical pattern; on immunosuppressive DMT</td>
<td>PET-CT; biopsy if indicated</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLINICAL</strong></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>Neurologic examination (EDSS)</td>
<td>Every visit; minimum annually</td>
<td>Stable or improved</td>
<td>If worsening: MRI, DMT optimization discussion</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Relapse frequency</td>
<td>Continuous; review at each visit</td>
<td>Zero relapses (NEDA goal)</td>
<td>Any relapse triggers MRI and DMT reassessment</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Walking speed (T25FW)</td>
<td>Annually</td>
<td>Stable or improved</td>
<td>If worsening: PT referral, dalfampridine consideration</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Cognition (SDMT or MoCA)</td>
<td>Annually</td>
<td>Stable (&gt;4 point decline on SDMT significant)</td>
<td>Cognitive rehab referral; medication review</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Depression screening (PHQ-9)</td>
<td>Annually; more often if symptoms</td>
<td>Score &lt;10</td>
<td>Antidepressant; psychiatry referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Fatigue (MFIS or FSS)</td>
<td>Each visit</td>
<td>Stable or improving</td>
<td>Fatigue management optimization</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>IMAGING</strong></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>MRI brain with contrast</td>
<td>Annually; 3-6 months after DMT switch</td>
<td>No new/enlarging T2 lesions; no enhancing lesions</td>
<td>New activity: DMT escalation discussion</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>MRI spine</td>
<td>Annually or with new symptoms</td>
<td>No new cord lesions</td>
<td>New lesions: DMT reassessment</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Macular OCT</td>
<td>Baseline; 3-4 months on S1P modulators; then annually</td>
<td>No macular edema; stable RNFL</td>
<td>Macular edema: discontinue S1P modulator; ophthalmology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>LABORATORY</strong></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with differential</td>
<td>q6 months on lymphocyte-depleting DMTs; annually others</td>
<td>Per DMT-specific thresholds (see Section 1B)</td>
<td>Adjust or discontinue DMT per protocol</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>LFTs</td>
<td>Per DMT schedule; more frequent early on</td>
<td>AST/ALT &lt;3x ULN</td>
<td>Hold DMT if &gt;3x; resume if resolves</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>JCV antibody with index</td>
<td>q6 months on natalizumab</td>
<td>Negative preferred; monitor index if positive</td>
<td>Rising index: risk counseling; consider DMT switch</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Immunoglobulins (IgG)</td>
<td>Annually on anti-CD20 therapies</td>
<td>IgG &gt;400 mg/dL</td>
<td>If low: infection precautions; consider IVIG replacement</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Vitamin D, 25-OH</td>
<td>Annually</td>
<td>&gt;40 ng/mL (target &gt;50)</td>
<td>Increase supplementation if low</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td><strong>ALEMTUZUMAB-SPECIFIC (48 months after last infusion)</strong></td>
<td></td>
<td></td>
<td></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
<tr>
<td>CBC with platelets</td>
<td>Monthly x 48 months</td>
<td>Platelets &gt;100K</td>
<td>If low: hold; hematology consult for ITP</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>TSH</td>
<td>q3 months x 48 months</td>
<td>Normal</td>
<td>If abnormal: endocrine consult</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
</tr>
<tr>
<td>Serum creatinine + UA</td>
<td>Monthly x 48 months</td>
<td>Stable creatinine; no RBCs/protein in UA</td>
<td>If abnormal: nephrology consult for anti-GBM disease</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Disposition</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discharge home</strong></td>
<td>Mild symptom worsening attributable to pseudorelapse (infection treated, heat exposure resolved); stable neurologic exam; able to care for self or adequate caregiver support; reliable follow-up</td>
</tr>
<tr>
<td><strong>Admit to floor</strong></td>
<td>Moderate-severe acute relapse requiring IV steroids; functional decline preventing safe discharge; diagnostic workup for suspected PML or CNS infection; severe medication side effect requiring monitoring</td>
</tr>
<tr>
<td><strong>Admit to ICU</strong></td>
<td>Severe myelitis with respiratory compromise (NIF declining toward -20 cm H2O); brainstem involvement with airway risk; severe infusion reaction; suspected PML with rapid deterioration</td>
</tr>
<tr>
<td><strong>Transfer to higher level</strong></td>
<td>PLEX needed but unavailable; MS specialist not available for complex decision-making (PML management, severe breakthrough); MRI unavailable for urgent imaging</td>
</tr>
<tr>
<td><strong>Outpatient follow-up</strong></td>
<td>Every 3-6 months for stable patients; q1-3 months during DMT transition or active disease; annually minimum for established stable patients</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Evidence Level</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual MRI surveillance for subclinical disease activity</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34139157/">Wattjes MP et al. Lancet Neurol 2021 (MAGNIMS-CMSC-NAIMS)</a></td>
</tr>
<tr>
<td>NEDA (No Evidence of Disease Activity) as treatment target</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28698253/">Giovannoni G et al. Neurology 2017</a></td>
</tr>
<tr>
<td>JCV antibody monitoring for PML risk stratification</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/22316447/">Bloomgren G et al. NEJM 2012</a></td>
</tr>
<tr>
<td>Extended interval dosing of natalizumab reduces PML risk</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30938869/">Zhovtis Ryerson L et al. Ann Neurol 2019</a></td>
</tr>
<tr>
<td>Anti-CD20 therapies effective in RRMS and PPMS</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28002679/">Hauser SL et al. NEJM 2017 (OPERA)</a></td>
</tr>
<tr>
<td>Vitamin D supplementation reduces relapse rate</td>
<td>Class I, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/31594857/">Hupperts R et al. Neurology 2019 (SOLAR)</a></td>
</tr>
<tr>
<td>Dalfampridine improves walking speed</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/19249634/">Goodman AD et al. Lancet 2009</a></td>
</tr>
<tr>
<td>Exercise improves fatigue and quality of life</td>
<td>Class I, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26358158/">Heine M et al. Cochrane 2015</a></td>
</tr>
<tr>
<td>Smoking cessation slows disability progression</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/23365092/">Hedstrom AK et al. Brain 2013</a></td>
</tr>
<tr>
<td>Cognitive rehabilitation improves cognitive outcomes</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/23091072/">Chiaravalloti ND et al. Neurology 2013</a></td>
</tr>
<tr>
<td>S1P modulators: macular edema and cardiac monitoring required</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20089954/">FDA label; Cohen JA et al. NEJM 2010 (fingolimod)</a></td>
</tr>
<tr>
<td>Alemtuzumab: secondary autoimmunity monitoring for 48 months</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18946064/">CAMMS223 investigators NEJM 2008</a></td>
</tr>
<tr>
<td>Pregnancy planning with DMT washout periods</td>
<td>Class III, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/24614515/">Bove R et al. Nat Rev Neurol 2014</a></td>
</tr>
<tr>
<td>Vaccinations before immunosuppressive DMTs</td>
<td>Expert consensus</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30366971/">Farez MF et al. Neurology 2019 (AAN guidelines)</a></td>
</tr>
</tbody>
</table>
<hr />
<h2 id="change-log">CHANGE LOG<a class="headerlink" href="#change-log" title="Permanent link">&para;</a></h2>
<p><strong>v1.0 (January 27, 2026)</strong>
- Initial template creation for MS chronic management
- Comprehensive DMT monitoring protocols by drug class
- Symptom management for fatigue, spasticity, pain, bladder, depression, cognition, gait
- Vaccination guidance and live vaccine contraindications
- Pregnancy planning section with DMT-specific washout requirements
- PML surveillance protocols for natalizumab and other high-risk DMTs
- Structured dosing format for order sentence generation
- Full setting coverage (ED, HOSP, OPD, ICU) for monitoring and treatment</p>
<hr />
<h2 id="appendix-a-dmt-monitoring-schedule-summary">APPENDIX A: DMT Monitoring Schedule Summary<a class="headerlink" href="#appendix-a-dmt-monitoring-schedule-summary" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>DMT</th>
<th>Labs</th>
<th>Lab Frequency</th>
<th>Imaging</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interferons</strong></td>
<td>CBC, LFTs, TSH</td>
<td>q3-6 months; TSH annually</td>
<td>Annual MRI</td>
<td>Depression screening</td>
</tr>
<tr>
<td><strong>Glatiramer</strong></td>
<td>None routine</td>
<td>N/A</td>
<td>Annual MRI</td>
<td>Injection site monitoring</td>
</tr>
<tr>
<td><strong>Dimethyl/Diroximel fumarate</strong></td>
<td>CBC (ALC), LFTs</td>
<td>q6 months</td>
<td>Annual MRI + PML surveillance</td>
<td>Discontinue if ALC &lt;500 x 6 months</td>
</tr>
<tr>
<td><strong>Teriflunomide</strong></td>
<td>LFTs, CBC, BP</td>
<td>Monthly x 6 mo, then periodic</td>
<td>Annual MRI</td>
<td>Pregnancy test PRN; teratogenic</td>
</tr>
<tr>
<td><strong>Fingolimod</strong></td>
<td>CBC, LFTs</td>
<td>q6-12 months</td>
<td>Annual MRI + PML surveillance</td>
<td>Macular OCT; first-dose cardiac monitoring</td>
</tr>
<tr>
<td><strong>Siponimod</strong></td>
<td>CBC, LFTs</td>
<td>q6-12 months</td>
<td>Annual MRI</td>
<td>CYP2C9 genotype; macular OCT</td>
</tr>
<tr>
<td><strong>Ozanimod/Ponesimod</strong></td>
<td>CBC, LFTs</td>
<td>q6-12 months</td>
<td>Annual MRI</td>
<td>Macular OCT at 3-4 mo then annually</td>
</tr>
<tr>
<td><strong>Cladribine</strong></td>
<td>CBC</td>
<td>Months 2 and 6 each treatment year</td>
<td>Annual MRI</td>
<td>ALC &gt;800 before year 2; malignancy screen</td>
</tr>
<tr>
<td><strong>Natalizumab</strong></td>
<td>JCV Ab, CBC, LFTs</td>
<td>JCV q6 months</td>
<td>MRI q3-6 mo (high risk) or q6-12 mo</td>
<td>REMS; extended dosing option</td>
</tr>
<tr>
<td><strong>Anti-CD20s</strong></td>
<td>Hep B, IgG, CBC</td>
<td>IgG annually; others periodic</td>
<td>Annual MRI</td>
<td>Infection monitoring</td>
</tr>
<tr>
<td><strong>Alemtuzumab</strong></td>
<td>CBC monthly, TSH q3mo, Cr/UA monthly</td>
<td>x 48 months after last dose</td>
<td>Annual MRI</td>
<td>REMS; autoimmunity monitoring</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-b-pml-risk-stratification-natalizumab">APPENDIX B: PML Risk Stratification (Natalizumab)<a class="headerlink" href="#appendix-b-pml-risk-stratification-natalizumab" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>PML Risk</th>
<th>Monitoring Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>JCV antibody NEGATIVE</td>
<td>Very low (&lt;0.1 per 1000)</td>
<td>JCV q6 months; annual MRI</td>
</tr>
<tr>
<td>JCV antibody POSITIVE, index &lt;0.9, no prior IS</td>
<td>Low (~0.5 per 1000)</td>
<td>JCV q6 months; MRI q6-12 months</td>
</tr>
<tr>
<td>JCV antibody POSITIVE, index 0.9-1.5, no prior IS</td>
<td>Moderate (~2 per 1000)</td>
<td>JCV q6 months; MRI q6 months; consider EID</td>
</tr>
<tr>
<td>JCV antibody POSITIVE, index &gt;1.5, no prior IS</td>
<td>High (~5-6 per 1000)</td>
<td>JCV q6 months; MRI q3-6 months; consider DMT switch</td>
</tr>
<tr>
<td>JCV antibody POSITIVE + prior immunosuppression</td>
<td>Very high (~10+ per 1000)</td>
<td>Strong consideration for DMT switch</td>
</tr>
<tr>
<td>&gt;24 months treatment duration</td>
<td>Increases risk</td>
<td>Factor into overall risk assessment</td>
</tr>
</tbody>
</table>
<p><strong>EID = Extended Interval Dosing</strong> (q6 weeks instead of q4 weeks) - associated with ~90% reduction in PML risk</p>
<p><strong>PML Warning Signs:</strong>
- Subtle cognitive changes, confusion
- Personality or behavioral changes
- Visual disturbances (homonymous hemianopia)
- Hemiparesis, ataxia
- New speech difficulties</p>
<p><em>If PML suspected: STOP natalizumab immediately; STAT MRI brain; CSF JCV PCR; neurology consultation</em></p>
<hr />
<h2 id="appendix-c-dmt-washout-periods-for-pregnancy">APPENDIX C: DMT Washout Periods for Pregnancy<a class="headerlink" href="#appendix-c-dmt-washout-periods-for-pregnancy" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>DMT</th>
<th>Washout Required</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glatiramer acetate</td>
<td>None</td>
<td>May continue if needed; preferred in pregnancy</td>
</tr>
<tr>
<td>Interferon-beta</td>
<td>None to minimal</td>
<td>Limited data; can continue if high activity</td>
</tr>
<tr>
<td>Dimethyl/Diroximel fumarate</td>
<td>Minimal (short half-life)</td>
<td>Stop when pregnancy confirmed</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td>Accelerated elimination required</td>
<td>Cholestyramine 8g TID x 11 days; verify level &lt;0.02 mg/L</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>2 months</td>
<td>Rebound risk; monitor closely</td>
</tr>
<tr>
<td>Siponimod</td>
<td>10 days</td>
<td>Shorter half-life than fingolimod</td>
</tr>
<tr>
<td>Ozanimod</td>
<td>7 days</td>
<td>Includes active metabolites</td>
</tr>
<tr>
<td>Ponesimod</td>
<td>7 days</td>
<td>Short half-life</td>
</tr>
<tr>
<td>Cladribine</td>
<td>6 months</td>
<td>Applies to both partners</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>Until pregnancy confirmed</td>
<td>Can continue through pregnancy in high-activity MS (shared decision)</td>
</tr>
<tr>
<td>Ocrelizumab</td>
<td>6-12 months</td>
<td>B-cell recovery variable; check CD19 count</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>6 months</td>
<td>B-cell recovery variable</td>
</tr>
<tr>
<td>Ublituximab</td>
<td>6 months</td>
<td>B-cell recovery variable</td>
</tr>
<tr>
<td>Alemtuzumab</td>
<td>4 months</td>
<td>After last infusion</td>
</tr>
</tbody>
</table>
<hr />
<div id="comments-container"></div>







  
  






                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>